Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVAC-2 Phase 2 in Healthy Adults
NCT05209009Phase 2Completed
- Sponsor
- University of Saskatchewan
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing COVAC-2 with Placebo (2 arms). Primary endpoint: Assessment of the safety and tolerability of COVID-19 vaccine (COVAC-2) at 365 days. Started Aug 2022; status: completed.
02
Drugs
COVAC-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05209009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05209009.